Speciality Medicines IPO
Market Sentiment
Market Lot Size
IPO Details
IPO Reservation
Financial Analysis
| Metric | 2024 | 2025 | Oct 2025 |
|---|---|---|---|
| Revenue | 27.66 | 58.54 | 36.93 |
| Expense | 23.10 | 49.85 | 30.80 |
| Profit (PAT) | 2.93 | 8.61 | 6.06 |
| Total Assets | 22.68 | 39.98 | 45.57 |
| Company | P/E | EPS | Market Cap (Cr) |
|---|---|---|---|
| Remus Pharmaceuticals Limited | 12.25 | 65.21 | 15 |
| Trident Lifeline Limited | 27.59 | 10.22 | 18 |
| Mono Pharmacare Limited | 13.87 | 1.75 | 10 |
Promoters: Parth B Goyani and Goyani Sumit Babubhai
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | 43.44% |
Company Information
One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products. Further, the company has around 7 registered products overseas, and 54 products are in the registration process across 5 countries.
| Purpose | Amount (Cr) |
|---|---|
| Setting up of the Research and Development (R&D) Centre | 13.31 |
| Product registration in the international markets | 2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | 1.75 |
| To Meet Working Capital Requirements | 12.00 |
| General Corporate Purpose | - |
Resources & Documents
Speciality Medicines Ltd., 913, One World West, S. No. 396, FP 119,, Village- Vejalpur, Ahmadabad City,, Ahmedabad, Gujarat, India,, Ahmedabad, Gujarat, 380051
Speciality Medicines has set a price band of Rs 117–Rs 124 per share for an issue size of Rs 29 crore. The stock listed flat against its issue price.
One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products.
The issue is promoted by Parth B Goyani and Goyani Sumit Babubhai with Unicon Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Setting up of the Research and Development (R&D) Centre (Rs 13 crore) and Product registration in the international markets (Rs 3 crore).
Current grey market activity shows a flat premium, indicating muted unofficial demand. Final subscription data records overall subscription at 2.19x, retail at 0.85x, QIB at 96.24x, NII at 1.77x.
On fundamentals, the company is posting revenue growth of 111.6%, a profit margin of 14.7%, return on equity of 37.9% in its most recent reported period. Listed peers in this segment include Trident Lifeline Limited (P/E 27.59x, market cap Rs 18 crore) and Remus Pharmaceuticals Limited (P/E 12.25x, market cap Rs 15 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Neutral stance — the data is mixed and the risk-reward is balanced rather than one-sided. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!